spacer
home > ict > autumn 2018 > clinical complexities
PUBLICATIONS
International Clinical Trials

Clinical Complexities

ICT: What are the main challenges faced by pharmaceutical companies when moving a candidate compound from the discovery lab through to first-inhuman (FIH) studies?

Torkel Gren and Anders Millerhovf: Moving a promising compound from the laboratory to the clinic is a complex, multistage challenge. You need to coordinate API production with formulation development and trial planning. The only way to do this effectively is for the teams involved in each of these processes to communicate properly.

Specific challenges include the limited quantities of API that are available, the need to develop formulations appropriate for FIH studies and for later-stage trials in parallel, and the ability to adapt to clinical protocol revisions. Effective communication between supply, formulation, and trial teams is vital, and achieving this can be a challenge, particularly if several different contractors are involved.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Torkel Gren is Senior Director, and Science and Technology Officer at Recipharm. He holds degrees in pharmacy and business administration, as well a PhD in pharmaceutics from Uppsala University, Sweden. Torkel has worked in the pharma industry since 1988 and has held a number of scientist and manager positions in Europe and the US. He was lead formulator and co-inventor of Detrol OD/Detrusitol SR. Torkel is Vice Chairman of the board of the Swedish Pharmaceutical Society.

Anders Millerhovf is Chief Executive Officer at Clinical Trial Consultants. He holds a degree in medical biology from Linkoping University, Sweden. Anders has worked in the life sciences industry since 2002 and has focussed on Phase 0 to Phase 2a projects in various project management and director positions. He has been a partner at Clinical Trial Consultants since 2012.
spacer
Torkel Gren
spacer
spacer
spacer
Anders Millerhovf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

International biomed specialist appoints WHP to deliver key expansion project

New state of the art cleanroom facilities will enable a leading international gene and cell therapy company to expand its bioprocessing operations and manufacturing capabilities.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement